In a decisive move that could reshape the landscape of labor relations within one of South Korea’s most influential conglomerates, the labor union at Samsung Biologics has voted overwhelmingly to break away from the Samsung Group’s super-company union and pursue independent negotiations with management. The vote, held from June 24 to June 28, 2026, saw 2,479 out of 4,005 eligible union members casting ballots, with a striking 96.5% supporting the proposal to leave the umbrella organization, according to reports from Yonhap Infomax and Yonhap News.
This landslide approval wasn’t just a routine procedural matter—it reflected months of mounting frustration among Samsung Biologics union members over stalled collective bargaining talks and a growing sense that their specific needs were being lost in the shuffle of a much larger union apparatus. As a union spokesperson explained to Yonhap News, “There is a great need to switch to an independent company-based union system to more directly and quickly reflect the understanding and demands of union members.”
The administrative process to finalize the departure is expected to be completed within days of the vote, the union said. This makes Samsung Biologics only the second union to exit the Samsung Group’s super-company union, following the earlier departure of the first union at Samsung Electro-Mechanics. The super-company union, established in February 2024, brings together unions from Samsung Biologics, Samsung Electronics, Samsung Display, and Samsung Fire & Marine Insurance, and boasts a combined membership of around 73,000. However, recent exits—including that of Samsung Biologics—have dealt a blow to the organization’s cohesion and bargaining power.
The decision by Samsung Biologics’ union to go it alone was not made lightly. Since December 2025, the union and management have been locked in negotiations over pay raises and improvements to personnel systems, but talks have repeatedly stalled. This deadlock prompted the union to escalate its actions, first with a partial strike from April 28 to 30, 2026, and then with a full-scale walkout involving approximately 2,800 members from May 1 to 5. Afterward, the union shifted to a legal compliance strike—refusing overtime and holiday work—starting May 6, a move that has reportedly caused some disruptions to production processes.
Despite these measures, a clear resolution has remained elusive. The union’s leadership cited the lack of tangible benefits from remaining under the super-company union’s umbrella as a key factor in their decision to seek independence. According to Yonhap News, “The strategic judgment was that there was little practical benefit to be gained from super-company union activities while negotiations with management were at a standstill.” The union’s hope is that by negotiating as an independent entity, it can more effectively advocate for its members’ interests and break the deadlock that has persisted for months.
The timing of this move is particularly significant. The union and management met for negotiations in late June and are scheduled to return to the bargaining table on July 1 and 2, 2026. Both sides appear to be in a cautious, exploratory phase. A union official told Yonhap Infomax, “We have only just resumed negotiations, and exploratory talks with management are ongoing.” The outcome of these talks could set a precedent not only for Samsung Biologics but for labor relations across the conglomerate.
Adding another layer of complexity, the union is awaiting the outcome of an injunction—essentially a restraining order—that could influence the practical aspects of its split from the super-company union. The decision on this legal matter is expected to come around mid-July 2026. Until then, both union and management are expected to continue efforts at negotiation, even as the legal status of the union’s new structure hangs in the balance.
The ripple effects of Samsung Biologics’ departure are already being felt within the broader Samsung Group labor movement. The super-company union was initially formed as a way to pool resources and increase bargaining power across multiple Samsung affiliates. However, it has faced internal challenges, particularly after a contentious labor-management agreement at Samsung Electronics led to dissatisfaction among some union members over differentiated performance bonuses. This dissatisfaction sparked a wave of defections, culminating in the high-profile exit of Samsung Biologics’ union.
For Samsung Biologics, the stakes are high. The company is a major player in the global biopharmaceutical manufacturing sector, and any sustained labor unrest could have significant operational and financial implications. Since the start of the legal compliance strike in early May, there have been reports of some production processes being disrupted, though the full extent of the impact remains unclear.
The union’s demands center on wage increases and improvements to the personnel system—issues that resonate with many workers across the Samsung empire. Yet, the union’s leadership believes that these issues are best addressed through direct negotiations with management, rather than through the broader, and at times unwieldy, framework of the super-company union. As one union representative put it, “If the administrative process is completed, the withdrawal procedure from the super-company union will be finished within a few days.”
Observers note that the outcome of the upcoming negotiations and the pending legal decision could influence whether other unions within Samsung Group follow suit. The first union to leave the super-company union, Samsung Electro-Mechanics’ primary union, set a precedent, but the subsequent formation of a new union at the same company that rejoined the super-company union shows that the landscape remains fluid and contested.
As the July negotiations approach, both union and management are keeping their cards close to their chests. The union describes the current phase as a “probe” or “exploratory battle,” suggesting that both sides are still feeling each other out and that a final resolution may be weeks away. Yet, with union members demonstrating such a strong mandate for independence, the pressure is on both sides to deliver results.
For now, the Samsung Biologics labor union stands at a crossroads, having chosen the path of independence in hopes of achieving the wage and workplace improvements its members have been seeking for months. Whether this bold gamble will pay off remains to be seen, but one thing is certain: the outcome will be closely watched by workers, managers, and labor activists far beyond the walls of Samsung Biologics.